Compelo Medical Devices - Latest industry news and analysis is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

ReCor PARADISE ultrasound platform wins CE mark

ReCor Medical has obtained CE mark approval for its Percutaneous Renal Denervation System (PARADISE) to treat resistant hypertension (HTN).

The PARADISE data from the F-I-M clinical trial demonstrated that systolic blood pressure was reduced by an average of 31 mm Hg in 7 patients at 60-day follow-up.

ReCor Medical CEO Mano Iyer said PARADISE is designed to offer a minimally invasive ultrasound therapy to resistant hypertension patients to help reduce their blood pressure.

"We are pleased with our First-In-Man clinical results as we prepare to introduce PARADISE in Europe,"Mano Iyer added.

PARADISE comprises a 6 French-compatible catheter with a cylindrical transducer that emits ultrasound energy uniformly all the way around the arterial wall while simultaneously cools the endothelium, which allows for a rapid and highly efficient renal denervation procedure.